Eleven of 13 treated CIDP patients with MN had a favorable response to mono- or combined immunotherapies such as CS, PE, and IVIg whereas anti-CNTN1 antibody-positive CIDP was frequently refractory to IVIg and CS. This evidence concerns the gene CNTN1 and chronic inflammatory demyelinating polyradiculoneuropathy.